Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monteith, D. K.
Right arrow Articles by Levin, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monteith, D. K.
Right arrow Articles by Levin, A. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 27, No. 3, 307-317 (1999)
DOI: 10.1177/019262339902700306

Evaluation of the Renal Effects of an Antisense Phosphorothioate Oligodeoxynucleotide in Monkeys

David K. Monteith

Isis Pharmaceuticals, Carlsbad, California 92008

Michelle J. Horner

Sierra Biomedical, Inc., Sparks, Nevada 89431

Nancy A. Gillett

Sierra Biomedical, Inc., Sparks, Nevada 89431

Madeline Butler

Isis Pharmaceuticals, Carlsbad, California 92008

Richard Geary

Isis Pharmaceuticals, Carlsbad, California 92008

Todd Burckin

Isis Pharmaceuticals, Carlsbad, California 92008

Tanya Ushiro-Watanabe

Isis Pharmaceuticals, Carlsbad, California 92008

Arthur A. Levin

Isis Pharmaceuticals, Carlsbad, California 92008, alevin@ isisph.com.

Antisense phosphorothioate oligodeoxynucleotides are therapeutic agents that provide target specificity resulting from Watson-Crick base pairing. However, there are nonspecific effects that in some instances result in toxicity. These compounds accumulate in the kidney and induce renal proximal tubular degeneration at high doses. The relationship between accumulation of phosphorothioate oligodeoxynucleotides in the kidney, indicators of renal toxicity, and histomorphology were investigated in rhesus monkeys. Monkeys received vehicle or an escalating dose regimen of 3, 10, 40, and 80 mg/kg of ISIS 2105 and were then evaluated for changes in clinical pathology indices, urinalysis parameters, and renal histopathology. Urinalysis revealed an increase in protein levels and a slight increase in blood content following the third 40 mg/kg dose and continuing through the 80 mg/kg doses, whereas other urinary markers of renal toxicity were unchanged. Creatinine clearance was slightly decreased in monkeys during the 80 mg/kg dose cycle. Granulation in the cytoplasm of proximal tubular epithelial cells was evident by microscopic examination of kidney and was present at all doses examined and increased with dose. Immunohistochemical staining localized the oligodeoxynucleotide within these granules. Histopathologic changes consisting of minimal to moderate tubular degeneration were present only at the higher doses of 40 and 80 mg/kg and at high tissue concentrations, and these changes occurred concurrent with functional alterations, whereas lower doses (≤10 mg/kg) did not affect a pathologic or functional change.

Key Words: Kidney toxicity • nephrotoxicity • oligonucleotide • primate renal function


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
N. Goebl, B. Berridge, V. J. Wroblewski, and P. L. Brown-Augsburger
Development of a Sensitive and Specific in Situ Hybridization Technique for the Cellular Localization of Antisense Oligodeoxynucleotide Drugs in Tissue Sections
Toxicol Pathol, June 1, 2007; 35(4): 541 - 548.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
C. A. Farman and D. J. Kornbrust
Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications
Toxicol Pathol, January 1, 2003; 31(1_suppl): 119 - 122.
[Abstract] [PDF]


Home page
J. Immunol.Home page
L. Sfondrini, D. Besusso, M. T. Zoia, M. Rodolfo, A. M. Invernizzi, M. Taniguchi, T. Nakayama, M. P. Colombo, S. Menard, and A. Balsari
Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice
J. Immunol., July 1, 2002; 169(1): 151 - 158.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. W. Lee, M. K. Song, K. H. Baek, Y. Park, J. K. Kim, C. H. Lee, H.-K. Cheong, C. Cheong, and Y. C. Sung
Effects of a Hexameric Deoxyriboguanosine Run Conjugation into CpG Oligodeoxynucleotides on Their Immunostimulatory Potentials
J. Immunol., October 1, 2000; 165(7): 3631 - 3639.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach
Catalytic Nucleic Acids: From Lab to Applications
Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348.
[Abstract] [Full Text] [PDF]